United Kingdom

Profile: Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

3:50pm BST
Change (% chg)

$0.04 (+1.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Biomerica, Inc., incorporated on September 22, 1971, is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians' offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations.

The Company's clinical laboratory products include Transglutaminase IgA ELISA, TPMT (40-Patient Kit), TPMT (8-Patient Kit), Antigliadin IgA ELISA Kit, IFA Elisa, Liver Kidney Microsomal Type 1, EPO ELISA, PTH ELISA (Intact), hs-CRP ELISA, Isletest GAD ELISA, Food Intolerance 14G Food Additives and E. coli O157. Its physicians' office products include Calprotectin, Microalbumin Screening (Bulk), Microalbumin Screening (Prof.), Salmonella, Shigella and hCG (Professional). Its home diagnostic tests include Aware Breast Self-Exam Kit, Screening-OTC, EZ Detect OTC (Retail Packaging), Fortel hCG Midstream and PSA (Bulk). The Company has manufactured and marketed tests for Myoglobin (Cardiac), H. Pylori (Digestive Disease), Histamine (Allergy), Self test for Colon Disease (Digestive) and Early detection of Diabetes (Diabetes), among others. Its InFoods IBS product is a diagnostic-guided therapy that is designed to allow for a personalized dietary treatment to improve Irritable Bowel Syndrome (IBS) patient outcomes.

The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company's diagnostic products use immunoassay technology. The Company's over-the-counter and professional rapid diagnostic products help manage existing medical conditions and save lives through early detection and diagnosis. The Company's diagnostic test kits are processed and assembled at its facilities in Irvine, California and in Mexicali, Mexico. The Company has a manufacturing facility in Mexicali, Mexico. The Company subleases facilities from and subcontracts with Lancer Orthodontics to provide labor and other services. The Company pursues the development of approximately two tests for the gastrointestinal market. The Company is licensed to design, develop, manufacture and distribute in-vitro diagnostic and medical devices.

The Company's GI focus has led to the development of a diagnostic-guided therapy for the treatment of various subtypes of IBS, such as IBS-C, IBS-D and IBS-M. The Company's subsidiaries include Biomerica de Mexico, which is established for future use as a maquiladora, and BioEurope GmbH, which acts as a distributor of Biomerica products in various markets.

Company Address

Biomerica Inc

17571 von Karman Ave
IRVINE   CA   92614-6207
P: +1949.6452111
F: +1949.5531231

Company Web Links